Thus, it seems likely that, in melanoma, changes in the overall scenario induced by therapeutic regimens, modifications in the tumor microenvironment or acquisition of additional genetic alterations likely direct mTORC1 and mTORC2 on different subsets of downstream targets and cellular bioenergetics processes during the progression of BRAF-mutated melanoma towards therapeutic resistance. This evidence concerns the gene BRAF and neoplasm.